ClinicalTrials.gg
RecruitingNCT07460882Updated Aug 21, 2026

The Impact of Low Sodium Salt Substitute Use on Serum Potassium Levels Among Patients With Hypertension

An interventional study of Low-sodium salt substitute in Hypertension, sponsored by Johns Hopkins University. Recruiting at 1 site in Bangladesh. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-21.

Sponsored by Johns Hopkins University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
607
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 50 studies in Hypertension by Johns Hopkins University — 10 open to participants now, 14 under way, none of them phase 3. Hypertension · Johns Hopkins University.

Planned enrollment
7th of 44
607 · median 138
Started
2026
with 6 others
No phase
39 of 50
6 open now
Primary completion
2027-03
later than 3 of 13 live
Registered
46th of 50
by date

Among the 50 studies in Hypertension by Johns Hopkins University, this one is the 7th largest by planned enrollment of the 44 interventional ones that give a count, is one of 7 that started in 2026, is one of 39 with no phase, reaches primary completion later than 3 of the 13 other live ones, and was the 46th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

10 of the 50 studies in Hypertension by Johns Hopkins University are open now, in 5 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Hypertension by Johns Hopkins University, or all of them as a file.
02

Study summary

The goal of this pre-post study is to assess the risk of hyperkalemia in adults with hypertension on medication in Bangladesh. The main questions it aims to answer are:

Is the risk of hyperkalemia after the initiation of Low Sodium Salt Substitute (LSSS) in people on antihypertensive medication (especially RASi) large enough to be concerned about its broad use in this population?

Does initiation of LSSS correct hypokalemia in people on antihypertensive medication (especially RASi) with low serum potassium levels?

Participants will be asked to reduce overall salt intake and to use LSSS on every occasion where regular salt would normally be used, including as cooking salt.

03

Conditions studied

  • Hypertension

Keywords

  • Hypertension
  • Low sodium salt substitute
  • Cardiovascular disease
  • RASi
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults ≥18 years with clinically diagnosed hypertension treated with medication [on a stable dose at least for 2 months]
  • Have a phone for contact

Exclusion criteria

Exclusion Criteria:

  • Those with baseline K ≥5.0 or K \<3.0 mmol/L
  • Advanced kidney disease ( \<45 ml/min/1.73m2).
  • Those on potassium sparing diuretics (e.g., spironolactone)
  • Other medical conditions determined by physicians (e.g., heart failure treated with medication; less than 12 months)
  • Dine out for dinner more than 3 times a week
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
607 participants (estimated)

Study arms

  • Experimental
    Low sodium salt substitute (LSSS)

    Participants are asked to reduce overall salt intake and to use LSSS on every occasion where regular salt would normally be used, including as cooking salt

    Dietary Supplement: Low-sodium salt substitute

Interventions

  • Dietary supplementLow-sodium salt substitute

    The low sodium salt substitute contains 25% potassium chloride (KCl range; 20%-35%)

06

What researchers measure

Primary outcomes

  1. Incident hyperkalemia (K ≥5.5 mmol/L)

    Time frame: 4 and 8 weeks

  2. Proportion of the correction of hypokalemia (from K <3.5 mmol/L to 3.5-5.0 mmol/L)

    Time frame: 4 and 8 weeks

Secondary outcomes

  1. Change in serum potassium levels

    Time frame: 4 and 8 weeks

  2. Change in systolic and diastolic blood pressure (mmHg)

    Time frame: 4 and 8 weeks

  3. Number of Participants Adherent to LSSS use

    Time frame: 4 and 8 weeks

07

Study locations

1 of 1 sites recruiting
  • The National Heart Foundation of Bangladesh
    Dhaka, Bangladesh
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared due to institutional review board restrictions and participant privacy considerations.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Mar 2027, 7 months after the start.

Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 7 months is below that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2026
First posted
Mar 10, 2026
StartActual
Aug 8, 2026
Primary completionEst.
Mar 31, 2027
CompletionEst.
Sep 30, 2027
Last update
Aug 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07460882
Collaborators
National Heart Foundation of Bangladesh, Vital Strategies
Responsible party
Sponsor
First posted
Mar 10, 2026
Start date
Aug 8, 2026
Primary completion
Mar 31, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Aug 21, 2026

Study contacts

Junichi Ishigami, MD, PhD
Contact
jishiga1@jhu.edu
14432877262
Sohel Reza Choudhury, MD, PhD
Contact
Junichi Ishigami, MD, PhD
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion